Estudo randomizado | Tixagevimabe-cilgavimabe para tratamento de pacientes internados com COVID-19.
18 Jul, 2022 | 13:36hComentário: The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients – News Medical
Conteúdos relacionados:
Comentário no Twitter
In pts hospitalised w/ COVID-19 receiving remdesivir and other standard care, tixagevimab–cilgavimab did not improve time to sustained recovery but was safe and mortality was lower vs placebo
From the ACTIV-3–TICO Study Group https://t.co/zaaXBQYl5t pic.twitter.com/xe0tmbFrZ9
— The Lancet Respiratory Medicine (@LancetRespirMed) July 11, 2022